Overview

The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
0
Participant gender:
All
Summary
This study aims to assess the effect of glucagon-like peptide-1 on cardiac output and transpulmonary gradient in patients undergoing right heart catheterisation for clinical reasons.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Papworth Hospital NHS Foundation Trust
Treatments:
Glucagon
Glucagon-Like Peptide 1
Criteria
Inclusion Criteria:

- Age over 18

- Able to give informed consent

- On the waiting list for heart transplant

- Left Ventricular Dysfunction awaiting catheterisation

Exclusion Criteria:

- Nicorandil, glibenclamide, Dipeptidyl Peptidase-4 inhibitor, Glucagon-Like Peptide-1
receptor agonist or insulin

- Women of child bearing age and breast feeding women

- Cardiac pacemaker or other implanted metallic device

- Unable to give informed consent